Bharat Immunolog (524663)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹24 per share provides a stated asset cushion; P/B of 1.13 means the stock trades close to book value.
• Market cap of ₹118 Cr is small, so any genuine business revival could have an outsized impact on the share price.
• The stock is at its 52-week high of ₹27.20, indicating some market interest despite weak fundamentals.

Concerns

• Latest quarter sales are ₹0 Cr with a net loss of ₹5 Cr; trailing sales growth of -100% means the operating engine is absent.
• ROE of -17.95% and ROCE of -9.27% show continued destruction of shareholder equity.
• Piotroski F-Score of 2/9 signals very weak financial health and a high probability of further deterioration.
• No dividend, no promoter holding disclosure, and a meaningless P/E of 0.00 create a lack of transparency and return.

AI Analysis

Reading Bharat Immunolog with Graham’s discipline, I turn first to earnings power. I find none: the latest quarter shows sales of ₹0 Cr and a net loss of ₹5 Cr, and sales growth is -100%. A P/E of 0.00 is not a valuation; it is an admission that no earnings exist. With ROE at -17.95% and ROCE at -9.27%, this balance sheet is being depleted, not built. The Piotroski F-Score of 2/9 confirms that nearly every operating and financial-health signal is weak. What remains is the stated book value of ₹24 per share, against a price of ₹27.20. At a P/B of 1.13, I am being asked to pay a small premium to book for a company that cannot generate sales. That premium is hard to justify. Graham would demand margin of safety; here the margin is only the book value, and it is shrinking every quarter as losses continue. The stock is sitting at its 52-week high of ₹27.20, while the underlying business is near zero—that divergence is a caution flag, not a catalyst. There is no dividend, promoter holding is not disclosed, and the market cap of ₹118 Cr is essentially a premium over an eroding asset base. Buffett’s advice applies: it is better to wait for a clear, demonstrated turnaround than to hope for one. I would need to see real revenue, narrowing losses, and evidence that book value is stable before this could qualify as a value investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer